Clinical outcomes following PAC/SIR/TAC therapy. (A) Cumulative incidence of grade II to IV acute GVHD. (B) Cumulative incidence of National Institutes of Health (NIH) moderate/severe chronic GVHD. (C) Overall survival. (D) Cumulative incidence of malignancy relapse post-HCT.